Background: Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) is the most common biologic subtype of breast cancer. Although adjuvant therapy has demonstrated a survival benefit in clinical trials, its use is poorly understood in the real-world among elderly breast cancer patients since age is a barrier to receiving adjuvant therapy. An examination of treatment patterns and outcomes associated with receipt of adjuvant/neoadjuvant therapy among elderly HR + HER2-breast cancer patients was undertaken. Methods: There were 18,470 HR + HER2-breast cancer patients from the linked SEER-Medicare database. Patients were diagnosed with stage I-III disease between 1/1/2007-12/31/2011, ≥66 years, enrolled in Medicare Parts A, B and D, and underwent breast cancer surgery after diagnosis. Time-varying Cox proportional hazards regression assessed overall survival. Results: There were 13,670 (74%) patients treated with adjuvant/neoadjuvant therapy and 4800 (26%) untreated. Compared to treated patients, untreated patients were older, had earlier stage, lower grade, smaller tumors, poorer performance, higher comorbidity score, and less use of a 21-gene recurrence score (RS) assay (p < 0.0001). In the survival model, increasing age, stage, tumor size, tumor grade, comorbidity score and poor performance were significantly associated with higher mortality risks, while use of an RS assay was associated with lower risks. The Cox model showed a 48% higher risk of death in untreated compared to treated patients. In a subset of 8967 patients with stage I disease, tumor size < 2.0 cm and grade 1/2; untreated patients had a 22% higher risk of death compared to treated patients. Conclusions: Older patients with favorable clinical characteristics (earlier stage, smaller tumor, lower grade) are less likely to be treated and have a
Introduction
Breast cancer is the most common invasive cancer in women and the second leading cause of death from cancer among women in the United States [1] .
One-percent of breast cancer occurs in men [2] [3] . Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) is the most common biologic subtype of breast cancer occurring in post-menopausal women and men [3] , and accounts for about 73% of incident cases [4] . About 50% of women diagnosed with breast cancer are over the age of 65 [5] . Breast cancer mortality has declined over the past few decades because of advances in awareness, earlier detection, and adjuvant treatments [6] [7] .
In general, patients with early-stage breast cancer undergo primary breast cancer surgery with or without radiation therapy. The National Comprehensive Cancer Network (NCCN) guidelines recommend adjuvant endocrine therapy for postmenopausal women with HR+ breast cancer for a five-year period following diagnosis [8] . The decision to add chemotherapy to adjuvant endocrine therapy is individualized based on patient factors such as age, tumor size, tumor grade, lymph node involvement, and the results of prognostic multigene assays like the 21-gene Recurrence Score (RS) assay [9] [10] [11] . Recent updates in the American Joint Committee on Cancer Criteria (AJCC) for breast cancer staging manual (8 th edition) have incorporated biomarkers and prognostic panel data to guide clinical decision-making.
The benefit of adjuvant therapy is poorly understood among older patients with breast cancer since age is a barrier to receiving adjuvant therapy and older patients are underrepresented in clinical trials [12] [13] . Observational studies have demonstrated that breast cancer mortality increases with age [14] and older age and comorbidities are associated with less aggressive treatment in non-metastatic breast cancer [13] [15] . We aimed to contribute to the existing evidence by examining adjuvant therapy patterns and survival outcomes among HR+HER2-, stage I-III patients with breast cancer using the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database.
Methods

Data Source
The SEER-Medicare database has been described previously [16] . The SEER 
Study Population
See Figure 1 for the schematic of the inclusion/exclusion process. Patients with a first primary breast cancer diagnosis were identified using SEER cancer site variables labeled "breast" by International Classification of Diseases for Oncology, Patients needed to be enrolled in Medicare Parts A and B for a full 12 months prior to diagnosis date and were excluded if breast cancer was diagnosed at the time of death or autopsy, and if enrolled in a health maintenance organization (HMO) any time within the 12 months prior to diagnosis as HMO claims are not available in the dataset. In July 2006, Medicare coverage was expanded to include prescription drugs under Medicare Part D. We had to further restrict our sample to patients diagnosed between 2007-2011 and enrolled in Part D for at least 1 month in the year after diagnosis date in order to capture patients eligible for adjuvant endocrine therapy. Patients also underwent breast cancer surgery (lumpectomy and mastectomy) within 6 months after diagnosis. Those who received oral or infused neoadjuvant/adjuvant systemic therapy from diagnosis up to 6 months after breast cancer surgery were part of the "treated" group while those who did not were classified as "untreated". The final analytic cohort included 18,470 patients with HR + HER2-breast cancer. and geographic region) and tumor characteristics (stage, grade, size, and histology) at the time of breast cancer diagnosis were extracted from the SEER registry file. SEER does not contain a measure of functional status, such as Eastern Cooperative Oncology Group (ECOG), we therefore used a proxy for functional status by Davidoff et al. [17] . This surrogate for functional status utilized Medicare claims to identify the following categories of healthcare services that are associated with poor functional status and difficulty in ambulation: oxygen and related respiratory supplies, wheelchair, walkers and supplies, home health services, and hospitalization, skilled nursing, or long-term care facility stays during the 12 months prior to diagnosis date. The National Cancer Institute (NCI) comorbidity index [18] assessed comorbidity burden using diagnosis and procedure codes in the Medicare claims files to identify the 15 non-cancer comorbidities from the Charlson Comorbidity Index [19] . A weight is assigned to each condition based on its 2-year mortality risk and these weights are summed to obtain an index for each patient. The index accounts for the number and severity of the conditions, with higher scores indicating a greater burden of comorbid disease. The NCI comorbidity index was also constructed using claims in the 12 months prior to diagnosis date. 
Statistical Analysis
Baseline characteristics of the study population were described using frequencies and percentages. The Chi-square test for categorical variables and ANOVA or t-test for continuous variables were used to test for differences between groups 
Results
Treatment Patterns
There were In a subgroup analysis comparing treated patients who received hormonal therapy, chemotherapy-only, and sequential therapy (chemotherapy followed by hormonal therapy); patients who received hormonal therapy were more likely to be older than 75 (46% vs. 21% and 22%; p < 0.0001), more likely widowed (35% vs. 26% and 27%; p < 0.0001), have stage I disease (64% vs. 23% and 26%; p < 0.0001), tumor grade I (32%, 16% and 16%; p < 0.0001), tumor size < 2.0 cm (68% vs. 40% and 41%; p < 0.0001), poorer performance (11% vs. 6% and 7%; p < 0.0001), and NCI comorbidity score ≥ 2 (18% vs. 14% and 16%; p = 0.0010) compared to patients who received chemotherapy-only and sequential therapy respectively (data not shown). Patients who received chemotherapy-only were more likely to have had radiotherapy (73% vs. 59% and 57%; p < 0.0001) compared to patients who received hormonal therapy and sequential therapy.
Patient Characteristics
Survival Outcomes
The mean and median follow-up time for the overall cohort was 48. Adjusting for demographic and clinical characteristics in Table 3 , untreated patients exhibited a 48% higher risk of death compared to treated patients. Increasing age, male gender, being widowed, poor performance, increasing stage, increasing tumor size, increasing tumor grade, and increasing comorbidity score were significantly associated with higher mortality risks. Receipt of genomic testing was associated with a 45% reduction in mortality risk. Prior radiotherapy was associated with a 41% reduction in mortality risk, and black African ancestry was associated with a 16% reduction in mortality risk compared to whites, after adjusting for all other variables in the model. In a subset of 8967 patients with stage I disease, tumor size < 2.0 cm and tumor grade 1 or grade 2; untreated patients had a 22% higher risk of death compared to treated patients. In the subset of treated patients, those receiving sequential chemotherapy plus hormonal therapy exhibited a 26% (HR = 1.26; 95% CI: 1.01 -1.58) higher risk of death compared to hormonal therapy alone, and there was no mortality risk difference with chemotherapy-only (HR = 1.10; 95% CI: 0.94 -1.30) compared to hormonal therapy, after adjusting for demographic and clinical characteristics (data not shown).
Discussion
We evaluated the predictors of neoadjuvant/adjuvant therapy receipt and survival among Medicare beneficiaries diagnosed with HR + HER2-breast cancer and found that older patients with more favorable disease characteristics (earlier stage, smaller tumor size, lower tumor grade) were less likely to receive neoadjuvant/adjuvant therapy and had a higher risk of death compared to neoadjuvant/adjuvant treated patients, controlling for other competing causes of mortal-Journal of Cancer Therapy ity such as age, co-morbidity burden, and poor performance. Our multivariate survival model also demonstrated that after adjusting for tumor characteristics and neoadjuvant/adjuvant treatment, increasing co-morbidity score was associated with increasing mortality risk, similar to a recent study [22] . The logistic regression model demonstrated that increasing age was associated with lower likelihood of therapy independent of performance status, co-morbidities and tumor characteristics, suggesting that physicians may be under-treating otherwise healthy older patients. Older patients represent a heterogeneous population in terms of fitness, and chronological age alone should not contraindicate life-prolonging or curative treatment. The primary element of curative therapy for early-stage breast cancer is surgery. The International Society of Geriatric Oncology (SIOG) panel recommends radiation therapy and adjuvant systemic treatment after breast-conserving surgery in all older patients with breast cancer [23] . The decision to use adjuvant chemotherapy should not be based on age, but on several factors that include comorbidities, functional status, life expectancy, treatment tolerance, patient preference and risk for local recurrence [24] [25] . Although adjuvant systemic therapy has clear benefits in patients with HR+ early breast cancer [26] , the treatment rate in our older aged cohort was low. Prior studies show that patients over the age of 80 are only half as likely as younger patients to have a discussion about tamoxifen with their physicians due to physician concerns about side effects and treatment adherence [27] [28].
Overall, only 16% of our study population had genomic testing and this was associated with a higher likelihood of receiving neoadjuvant/adjuvant therapy as well as a 45% reduction in mortality risk compared to patients who did not have the test. A recent meta-analysis of 15 studies that investigated the impact of RS assays on adjuvant treatment decisions, reported that the additional information provided by the test changed the recommendation for adjuvant treatment in 30% of cases with the majority being a de-escalation of chemoendocrine therapy to adjuvant endocrine therapy alone [29] . In our study, we found that the rates of sequential therapy with chemotherapy followed by hormonal therapy decreased, while the use of hormonal therapy increased in association with the RS assay. Other trials showed that the benefit of adding chemotherapy to tamoxifen was mainly seen in patients with a high RS and no significant benefit from the addition of chemotherapy was noted in the low and intermediate RS risk groups
[11] [30] . However, given the nature of administrative claims data, we were unable to determine results of RS assays and RS score risk groups. In addition, RS assays are usually ordered for patients who are candidates for chemotherapy use.
It's possible that the higher mortality risk observed in the non-RS assay group was due to poorer fitness and tolerability concerns that also precluded them from chemotherapy use and RS assay testing. A recent sub analysis from the MINDACT study demonstrated that 24% of patients with node negative small tumors (<1 cm) who were identified as clinical low risk, but genomic high risk, derived a benefit from chemotherapy [31] . While another study found that patients with indolent threshold (ultralow-risk) on the 70-gene assay genomic test have a significantly low risk of mortality after surgery without adjuvant systemic treatment [32] . This adds further support that tumor biology is an important factor when considering adjuvant treatments.
Interestingly, our finding that patients of black African ancestry have lower mortality risk compared to white patients is discordant with prior research.
African American women have lower incidence of breast cancer but worse survival when compared to white women [33] [34] [35] . Many have postulated that the survival disparity is related to access to healthcare, treatment differences or socioeconomic factors [36] [37] [38] and race alone is seen as an independent predictor of survival [39] . However, a more recent SEER-Medicare analysis confirmed that after matching patients on treatment as well as demographics, comorbidities, and tumor characteristics at presentation, there was very little difference in survival between black and white women [40] .
Receipt of treatment and survival varied by marital status, similar to patterns observed in prior oncology research [41] 
Strengths & Limitations
A major strength of this study is that it is a large population-based sample that The second limitation involves an imputation method for performance status since the database does not include a direct measure for ECOG performance status. We identified diagnostic and procedure codes for specific healthcare resource use that have been shown to be predictive of functional status. Although this surrogate for poor performance may not adequately assess functional status for all patients in our study, it improves the validity of this observational study by attempting to control for such an important confounding variable.
Third, Medicare claims data are created for payment purposes and although we are able to detect who received the RS assay, we do not know the results of the test or patients RS risk groups. The decision to forgo therapy in the older individual often involves many factors such as patient and family preferences, and/or physician concerns for poor tolerance of therapy due to comorbidity and declining organ function [47] ; and the SEER-Medicare database does not take into account these physician and patient preferences with regard to treatment.
Similarly, patients in the oral hormonal therapy group may be susceptible to misclassification bias as the data derived from administrative claims provide information on medications that were filled, but does not reflect actual medication exposure. To minimize the impact of these potentially misclassified individuals Journal of Cancer Therapy in the oral hormonal therapy group, we required evidence of at least two prescriptions and no gaps of at least 120 days between prescriptions to increase the likelihood that patients are actually taking the medicine.
Fourth, the use of overall survival as an endpoint should be interpreted with caution. Although overall survival is the most reliable and available survival measure, it may not be specific enough to provide information on survival related to breast cancer treatment. Therefore, it's not clear if the higher survival we observed among treated patients is due to fewer deaths from other competing causes or fewer deaths from breast cancer treatment. Finally, the data presented here are limited to Medicare enrollees and patients enrolled in HMO represent a gap in the SEER-Medicare database. HMO enrollees tend to be younger and healthier than beneficiaries in fee-for-service plans resulting in a biased loss of information using the Medicare claims data [16] .
Conclusion
Older patients with HR + HER2-resected breast cancer who have favorable disease characteristics (earlier stage, smaller tumor size and lower tumor grade)
were less likely to receive adjuvant/neoadjuvant therapy with hormonal and/or chemotherapy. Untreated patients with favorable disease characteristics had a significantly higher risk of death compared to treated patients, after controlling for comorbidities, poor performance and other patient characteristics. Additional research is needed to determine why adjuvant/neoadjuvant therapies are omitted among the older "fit" breast cancer patient population. 
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